Last Updated : April 19, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
relugolix (Orgovyx)
Therapeutic Area: Advanced prostate cancer
Draft recommendations posted for stakeholder feedback: May 1, 2024
End of feedback period: May 16, 2024
Draft Recommendation
nivolumab (Opdivo)
Therapeutic Area: Stage IIB or IIC melanoma, adjuvant
Draft recommendations posted for stakeholder feedback: May 1, 2024
End of feedback period: May 16, 2024
Draft Recommendation
epcoritamab (Epkinly)
Therapeutic Area: Relapsed or refractory diffuse large B-cell lymphoma
Draft recommendations posted for stakeholder feedback: May 1, 2024
End of feedback period: May 16, 2024
Draft Recommendation
elranatamab (Elrexfio)
Therapeutic Area: Relapsed or refractory multiple myeloma
Draft recommendations posted for stakeholder feedback: May 1, 2024
End of feedback period: May 16, 2024
Draft Recommendation
insulin icodec (Awiqli)
Therapeutic Area: Diabetes mellitus, type 2
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
bimekizumab (Bimzelx)
Therapeutic Area: Psoriatic arthritis
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
bimekizumab (Bimzelx)
Therapeutic Area: Ankylosing spondylitis
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area:
locally advanced unresectable or metastatic urothelial carcinoma (UC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Genito-urinary cancer (prostate cancer)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
acute myeloid leukemia (AML)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Alzheimer’s disease
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
generalized pustular psoriasis (GPP)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Retinal vein occlusion
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Generalized Myasthenia Gravis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Chronic lymphocytic leukemia (CLL).
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Metastatic urothelial cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Iron deficiency in adult patients with heart failure
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Last Updated : April 19, 2024